{"nctId":"NCT00107120","briefTitle":"The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive Disorder","startDateStruct":{"date":"2005-03"},"conditions":["Major Depressive Disorder"],"count":312,"armGroups":[{"label":"Escitalopram","type":"EXPERIMENTAL","interventionNames":["Drug: Escitalopram"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Escitalopram","otherNames":["Lexapro (TM)"]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patient must meet Diagnostic and Statistical Manual, Fourth Edition (DSM-IV) diagnostic criteria for Major Depressive Disorder.\n* Patient's current depressive episode must be at least 12 weeks in duration\n* Patient must have a parent or caregiver who must agree to accompany the patient to all clinic visits.\n\nExclusion Criteria:\n\n* Patients who currently meet DSM-IV criteria for:\n\n  1. attention deficit-hyperactivity disorder\n  2. obsessive-compulsive disorder\n  3. posttraumatic stress disorder\n  4. bipolar disorder\n  5. pervasive developmental disorder\n  6. mental retardation\n  7. conduct disorder\n  8. oppositional defiant disorder\n* Patients who are considered a suicide risk (have active suicidal ideation), who have made a suicide attempt, or who have ever been hospitalized because of a suicide attempt.","healthyVolunteers":false,"sex":"ALL","minimumAge":"12 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Children's Depression Rating Scale - Revised (CDRS-R) Total Score","description":"Change from baseline to week 8 in Children's Depression Rating Scale total score. The scale measures 17 depressive symptoms, of which 3 are rated 1-5 and 14 are rated 1-7 (1 = no symptom difficulties; 5 or 7 = severe clinically significant difficulties) for a total score range of 17-113.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-22.4","spread":"1.1"},{"groupId":"OG001","value":"-18.4","spread":"1.1"}]}]}]},{"type":"SECONDARY","title":"Clinical Global Impressions - Improvement","description":"Clinical Global Impressions - Improvement score at the end of week 8. The scale rates improvement or worsening of patient mental health relative to baseline on a scale from 1 (very much improved) to 7 (very much worse).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":"0.1"},{"groupId":"OG001","value":"2.5","spread":"0.1"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Children's Global Assessment Scale","description":"Change from baseline to week 8 in CGAS score which rates the patient's general level of functioning for the past 14 days on a scale of 1 (most impaired) to 100 (healthiest).","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","spread":"1.0"},{"groupId":"OG001","value":"12.4","spread":"1.0"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":4,"n":155},"commonTop":["Headache","Inflicted Injury","Nausea","Pharyngitis","Insomnia"]}}}